Ceftezole Sodium (Celoslin sodium, Falomesin sodium) is the sodium salt form of ceftezole, a semi-synthetic first-generation cephalosporin with antibacterial activity.

Ceftibuten Dihydrate(Sch-39720 dihydrate) is the dihydrate form of ceftibuten, a semisynthetic, beta-lactamase-stable, third-generation cephalosporin with antibacterial activity.

Ceftiofur is a semisynthetic, beta-lactamase-stable, broad-spectrum cephalosporin with antibacterial activity.

Ceftiofur HCl (U-67279A,Excenel hydrochloride) is a cephalosporin antibiotic, used to treat both Gram-positive and Gram-negative bacteria infection.

Ceftiofur sodium is a semisynthetic, beta-lactamase-stable, broad-spectrum cephalosporin with antibacterial activity.

Ceftizoxime is a semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. It is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms.

Ceftizoxime sodium(SKF-88373) is a semisynthetic cephalosporin antibiotic that is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms.

Ceftriaxone Sodium is the sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity.

Cefuroxime axetil, a prodrug of the cephalosporin cefuroxime, is a second generation oral cephalosporin antibiotic with in vitro antibacterial activity against several gram-positive and gram-negative organisms.

Cefuroxime Sodium is a cephalosporin effective against gram-positive and gram-negative bacteria with resistance to β-lactamase.

Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson’s disease through activating mitophagy.

Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson’s disease through activating mitophagy.

Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson’s disease through activating mitophagy.

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Celiprolol is a β1-adrenoceptor antagonist with partial β2 agonist activity.

Celiprolol is a β1-adrenoceptor antagonist with partial β2 agonist activity.

A unique collection of 506 small molecule compounds used for cell cycle and related diseases research.

CeMMEC1 is an N-methylisoquinolinone derivative that inhibits the second bromodomain of TAF1 (IC50=0.9 μM).

CeMMEC13 is an isoquinolinone that selectively inhibits the second bromodomain of TAF1 (IC50 = 2.1 µM).

Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. Cenicriviroc also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.

Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. Cenicriviroc also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.

Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. Cenicriviroc also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.

Centrinone (LCR-263) is a selective and reversible polo-like kinase 4 (PLK4) inhibitor with Ki of 0.16 nM.

Centrinone (LCR-263) is a selective and reversible polo-like kinase 4 (PLK4) inhibitor with Ki of 0.16 nM.

CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.

CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.

CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.

CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.